Cardiovascular Injury Due to SARS-CoV-2.

IF 3.1 Q2 MICROBIOLOGY Current Clinical Microbiology Reports Pub Date : 2021-01-01 Epub Date: 2021-03-05 DOI:10.1007/s40588-021-00160-0

Christina L Bugert, Victoria Kwiat, Isela C Valera, Joachim J Bugert, Michelle S Parvatiyar

{"title":"Cardiovascular Injury Due to SARS-CoV-2.","authors":"Christina L Bugert, Victoria Kwiat, Isela C Valera, Joachim J Bugert, Michelle S Parvatiyar","doi":"10.1007/s40588-021-00160-0","DOIUrl":null,"url":null,"abstract":"Purpose of review: The world is currently facing the largest global health crisis since the early 1900s due to a novel coronavirus. While SARS-CoV-2 infection causes predictable symptoms in COVID-19 patients, including upper respiratory distress and fever, the heterogeneity of manifestations is surprising. This review focuses on direct and indirect causes of myocardial injury in COVID-19 patients and highlights current knowledge, treatment strategies, and outstanding questions in the field.Recent findings: Data are emerging that highlight the extent of cardiovascular involvement in COVID-19 patients, including evidence that SARS-CoV-2 causes myocarditis and increases cardiac risk. The incidence of cardiac injury is much greater in patients with severe disease presentation and those in intensive care.Summary: During the past year, COVID-19 patient mortality rates have improved due to tailored pharmacological treatments and patient management strategies that address the unique presentation of symptoms, which will hopefully also reduce the incidence of cardiac injury.","PeriodicalId":45506,"journal":{"name":"Current Clinical Microbiology Reports","volume":"8 3","pages":"167-177"},"PeriodicalIF":3.1000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934983/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Clinical Microbiology Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40588-021-00160-0","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/3/5 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: The world is currently facing the largest global health crisis since the early 1900s due to a novel coronavirus. While SARS-CoV-2 infection causes predictable symptoms in COVID-19 patients, including upper respiratory distress and fever, the heterogeneity of manifestations is surprising. This review focuses on direct and indirect causes of myocardial injury in COVID-19 patients and highlights current knowledge, treatment strategies, and outstanding questions in the field.

Recent findings: Data are emerging that highlight the extent of cardiovascular involvement in COVID-19 patients, including evidence that SARS-CoV-2 causes myocarditis and increases cardiac risk. The incidence of cardiac injury is much greater in patients with severe disease presentation and those in intensive care.

Summary: During the past year, COVID-19 patient mortality rates have improved due to tailored pharmacological treatments and patient management strategies that address the unique presentation of symptoms, which will hopefully also reduce the incidence of cardiac injury.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

SARS-CoV-2 导致的心血管损伤。

审查目的：目前，由于新型冠状病毒的出现，世界正面临着自 20 世纪初以来最大的全球健康危机。虽然 SARS-CoV-2 感染会导致 COVID-19 患者出现可预测的症状，包括上呼吸道窘迫和发热，但其表现的异质性却令人吃惊。本综述重点探讨 COVID-19 患者心肌损伤的直接和间接原因，并着重介绍该领域的现有知识、治疗策略和悬而未决的问题：最近的发现：新出现的数据强调了 COVID-19 患者心血管受累的程度，包括 SARS-CoV-2 导致心肌炎和增加心脏风险的证据。总结：在过去的一年里，COVID-19 患者的死亡率有所改善，原因是针对独特的症状表现采取了有针对性的药物治疗和患者管理策略，这也有望降低心脏损伤的发生率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Clinical Microbiology Reports MICROBIOLOGY-

CiteScore

7.50

自引率

1.90%

发文量

期刊介绍： Current Clinical Microbiology Reports commissions expert reviews from leading scientists at the forefront of research in microbiology. The journal covers this broad field by dividing it into four key main areas of study: virology, bacteriology, parasitology, and mycology. Within each of the four sections, experts from around the world address important aspects of clinical microbiology such as immunology, diagnostics, therapeutics, antibiotics and antibiotic resistance, and vaccines. Some of the world’s foremost authorities in the field of microbiology serve as section editors and editorial board members. Section editors select topics for which leading researchers are invited to contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, which are highlighted in annotated reference lists. These timely reviews of the literature examine the latest scientific discoveries and controversies as they emerge and are indispensable to both researchers and clinicians. The editorial board, composed of more than 20 internationally diverse members, reviews the annual table of contents, ensures that topics address all aspects of emerging research, and where applicable suggests topics of critical importance to various countries/regions.